Mark Gustavson
Senior Director & Head of Computational Pathology Strategic Partnerships AstraZeneca
Seminars
Tuesday 23rd September 2025
Panel Discussion: Navigating the Common Pitfalls in Digital Pathology to Streamline CDx Development & Adoption
9:50 am
- What are the key strategies to overcome barriers to widespread adoption of digital pathology? And how can organizations build the necessary infrastructure to support digital pathology at scale?
- What are the commercial challenges facing digital pathology as a companion diagnostic and how can companies address these obstacles?
- What are the current regulatory challenges in getting digital pathology technologies approved for use as CDx, and how can these be addressed moving forward?
Tuesday 23rd September 2025
Computational Pathology – Clearing the Way for More Robust IHC Biomarker Diagnostics
8:10 am
- Computational pathology is the next revolution in pathology enabling the development of more robust and accurate biomarker diagnostics
- QCS (Quantitative Continuous Scoring) was developed to quantify both target protein expression and spatial heterogeneity of target expression
- Discussing how AstraZeneca are leveraging QCS to quantify target expression to predict response of our oncology therapeutics, including Datopotamab deruxtecan (TROP2)
